Mirum Pharmaceuticals, Inc. develops and commercializes medicines for rare diseases, with recurring updates centered on product sales, clinical readouts, regulatory interactions and employee equity grants. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis.
News about MIRM also covers clinical-stage programs including volixibat, an IBAT inhibitor for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, a monoclonal antibody designed to bind hepatitis B surface antigen for chronic hepatitis delta virus; and MRM-3379, a PDE4D inhibitor for Fragile X syndrome. Company updates report financial results, pipeline licensing activity and inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (Nasdaq: MIRM) reported Q2 2026 global net product sales of $176.2 million, up from $127.8 million a year earlier, and raised full‑year 2026 net product sales guidance to $680–$700 million. LIVMARLI sales reached $128.7 million (46% year‑over‑year growth) and Bile Acid Medicines delivered $47.5 million (20% growth).
Total operating expenses were $218.8 million, including $23.2 million cost of sales, $16.4 million non‑recurring IPR&D for the zilurgisertib license, $76.3 million R&D and $65.6 million SG&A, plus $37.3 million of stock‑based compensation, intangible amortization and other non‑cash items. Mirum issued $690 million of 0.00% convertible senior notes due 2032 and settled $237.2 million of 4.00% notes due 2029, ending Q2 with $561.3 million in unrestricted cash, cash equivalents and investments.
The FDA granted Breakthrough Therapy and Orphan Drug designations to volixibat for PSC‑related cholestatic pruritus. Following a pre‑NDA meeting, Mirum plans further FDA discussions before a potential volixibat NDA submission in H1 2027. Enrollment in the Phase 2b VANTAGE study in PBC is complete, with topline data expected Q1 2027. Additional milestones include Phase 3 brelovitug readouts in HDV in H2 2026, Phase 3 LIVMARLI EXPAND data in Q4 2026, and an FDA Priority Review of the zilurgisertib NDA in FOP with a PDUFA target date of September 26, 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, and will host a conference call to review the results and recent corporate progress.
The call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT with U.S. toll-free and international dial-in options, plus a webcast and archived replay via Mirum’s investor website.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that on July 10, 2026, its Board Compensation Committee granted inducement equity awards under the 2020 Inducement Plan to six new employees, comprising non-qualified stock options for 6,300 shares at an exercise price of $122.13 and 9,300 restricted stock units, with multi-year vesting schedules tied to continued service.
Mirum Pharmaceuticals (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) reported pivotal Phase 2 PROGRESS data for zilurgisertib in fibrodysplasia ossificans progressiva (FOP). In 63 patients ≥12 years, zilurgisertib showed large reductions in new and existing heterotopic ossification (HO) lesion volume and maintained low flare activity through Week 48. Zilurgisertib was generally well tolerated, with mainly mild to moderate adverse events. The FDA accepted the NDA with Priority Review for FOP patients ≥12 years, with a PDUFA target action date of September 26, 2026.
Mirum Pharmaceuticals (Nasdaq:MIRM) granted equity inducement awards to 8 new employees on June 10, 2026 under its 2020 Inducement Plan. Awards include non-qualified stock options for 10,100 shares at an exercise price of $94.00 and 13,350 RSUs.
Stock options vest over four years, with 25% after one year and the remainder monthly over 36 months. RSUs vest over three years in equal annual installments, all subject to continued service.
Incyte (Nasdaq: INCY) and Mirum Pharmaceuticals will present pivotal Phase 2 PROGRESS study results for investigational ALK2 inhibitor zilurgisertib in fibrodysplasia ossificans progressiva (FOP) at ENDO 2026 in Chicago, June 13-16, 2026.
The Cohort 1, placebo-controlled data supported the New Drug Application, which has an FDA Priority Review PDUFA date of September 26, 2026.
Mirum Pharmaceuticals (Nasdaq:MIRM) reported new data for three rare liver disease programs presented at EASL 2026.
Phase 2b VISTAS volixibat data in PSC showed clinically meaningful pruritus and serum bile acid reductions, Phase 2b AZURE-1 brelovitug data showed virologic and ALT responses in HDV, and LIVMARLI improved event-free survival in PFIC versus a real-world cohort. Mirum plans a 2026 NDA for volixibat and targets Phase 3 HDV topline data in 2H 2026.
Mirum Pharmaceuticals (Nasdaq:MIRM) will present new rare liver disease data at the EASL International Liver Congress 2026 in Barcelona from May 27-30, 2026.
Highlights include late-breaking Phase 2b results for volixibat in PSC, brelovitug in HDV, and clinical and real-world data for LIVMARLI (maralixibat) in PFIC and intrahepatic cholestasis of pregnancy.
Mirum Pharmaceuticals (Nasdaq:MIRM) granted equity inducement awards to 12 new employees under its 2020 Inducement Plan on May 11, 2026. Awards include non-qualified stock options for 22,950 shares at an exercise price of $106.17 and 31,300 RSUs, issued under Nasdaq Listing Rule 5635(c)(4).
Options vest over four years; RSUs vest over three years, subject to continued service.
Mirum Pharmaceuticals (Nasdaq:MIRM) priced $600.0 million of 0.00% convertible senior notes due 2032 in a Rule 144A private placement, with a $90.0 million option for additional notes.
Net proceeds are estimated at $583.8–$671.6 million, partly used to refinance 4.00% 2029 notes and for general corporate purposes.